Example: bankruptcy
HIGHLIGHTS OF PRESCRIBING INFORMATION
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.lenvima.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Differentiated Thyroid Cancer 1.2 Renal Cell Carcinoma 1.3 Hepatocellular Carcinoma
Clinical information guide - lenvima.com
www.lenvima.comPatients with locally recurrent or metastatic RAI-refractory DTC (N=392) All patients must have had radiographic evidence of disease progression within 12 months prior
OR Eisai Assistance Program 1-866-61-EISAI …
www.lenvima.comIf signed by legal representative, describe the nature of his/her relationship with the patient: Name of Patient Name of Legal Representative Signature
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
packageinserts.bms.com13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
HIGHLIGHTS OF PRESCRIBING INFORMATION - GSKpro
gskpro.com*Sections or subsections omitted from the full prescribing information are not listed. _____ FULL PRESCRIBING INF ORMATION . 1 INDICATIONS AND USAGE . 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease . TRELEGY ELLIPTA 100/62.5/25 mcg is indicated for the maintenance treatment of patients with chronic obstructive pulmonary ...
HIGHLIGHTS OF PRESCRIBING INFORMATION • Administer …
www.biogencdn.comFULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or
HIGHLIGHTS OF PRESCRIBING INFORMATION Use of …
www.rxabbvie.comFULL PRESCRIBING INFORMATION: CONTENTS* WARNING: SERIOUS INFECTIONS, MORTALITY,MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS,AND THROMBOSIS 1INDICATIONS AND USAGE 1.1 Rheumatoid Arthritis 1.2 Psoriatic Arthritis 1.3 Atopic Dermatitis 1.4 Ulcerative Colitis 2 DOSAGE AND ADMINISTRATION 2.1 …
BREYANZI (lisocabtagene maraleucel) suspension for ...
packageinserts.bms.com1 2.INDICATIONS AND USAGE BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell ... See the prescribing information for fludarabine and cyclophosphamide for